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Introduction: Vascular calciﬁcation (VC) associated to chronic kidney disease (CKD) is a com-
plex  phenomenon closely related to mineral bone metabolism disorders. Many  are the
factors implicated, as the drugs used in the treatment of CKD. Some in vitro studies suggest
that  electrolyte and acid–base disorders induced by haemodialysis (HD) may play a key role
in  VC.
Methods: We  analysed electrolyte and acid–base disorders that occur during an HD session
in  26 patients randomly assigned to 1.25 mM or 1.5 mM calcium bath.
Results: There is a calcium load in all the patients, independently of calcium bath concentra-
tion or basal serum calcium levels. At the end of the session, 100% of the patients dialysed
with 1.5 mM calcium bath have calcium serum levels >1.3 mM. However, this only occurs
in  15% of the patients dialysed with 1.25 mM calcium bath. During this calcium load, phos-
phorus levels persist uncontrolled. Besides, there is a progressive alkalinisation in all the
patients. In the end of the session 50% have serum bicarbonate >30 mM and 23% pH >7.5.
Conclusions: During HD sessions occur electrolyte and acid–base disorders that induce VC:
calcium load and alkalisation in presence of elevated phosphorus levels. It is necessary to
perform studies with kinetic models of calcium load and alkalinisation different from the
actual ones.
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Sesión  de  hemodiálisis:  la  tormenta  perfecta  para  la  calciﬁcación  vascular
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r  e  s  u  m  e  n
Introducción: La calciﬁcación vascular (CV) asociada a la enfermedad renal crónica (ERC) es un
fenómeno estrechamente ligado a las alteraciones en el metabolismo mineral óseo. Existen
muchos  factores implicados, entre ellos los fármacos empleados en el tratamiento de la
ERC.  Algunos estudios in vitro sen˜alan que las alteraciones electrolíticas y ácido-básicas
que  tienen lugar durante la sesión de hemodiálisis (HD) pueden jugar un papel clave en el
proceso de CV.
Métodos: Analizamos las alteraciones electrolíticas y ácido-básicas que tienen lugar durante
la  sesión de HD en 26 pacientes, empleando de forma aleatorizada concentraciones de calcio
en  el líquido de diálisis de 1,25 o 1,5 mM.
Resultados: En todos los pacientes, independientemente del ban˜o de calcio empleado, se
produce una ganancia de calcio. En el grupo de pacientes dializados con ban˜o de calcio
1,5  mM, el 100% ﬁnaliza la sesión con valores de calcio sérico > 1,3 mM, mientras que en el
de  1,25 mM,  esto solo ocurre en el 15%. Al inicio de la sesión, esta ganancia de calcio coincide
con  niveles de fósforo aún no controlado. Además, en todos los pacientes se observa una
alcalinización progresiva: el 50% ﬁnaliza la sesión con cifras de bicarbonato > 30 mM y el 23%
con pH > 7,5.
Conclusiones: Durante la sesión de HD se producen cambios electrolíticos y ácido-básicos
inductores de CV: ganancia de calcio y alcalinización en presencia de fósforo sérico ini-
cialmente elevado. Son necesarios estudios con modelos cinéticos de ganancia de calcio y
alcalinización diferentes a los actuales.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de  Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
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ascular calciﬁcation (VC), a process inherent to ageing, is
nﬂuenced by multiple classical cardiovascular risk factors,
uch as arterial hypertension, diabetes mellitus, obesity, and
yslipidaemia, amongst others.1 In the general population,
C takes place in the intimal arterial layer,2 affecting mainly
entral arteries (the aorta and its branches) and is linked to
ystemic atherosclerosis.3
Cardiovascular events are the primary cause of morbid-
ty and mortality in patients with chronic kidney disease
CKD).4 In these patients, 2 patterns of VC have been described:
redominantly intimal, and predominantly medial. However,
here is much debate regarding the differences between
ntimal calciﬁcation and medial calciﬁcation. There is no
eﬁnitive evidence to suggest that calciﬁcation isolated to
he media is distinct from the calciﬁcation that comes from the
atural history of atherosclerosis; nor is there deﬁnitive evi-
ence to the contrary.5,6 What is certain is that it is closely
elated to the mixture of metabolic and biological abnor-
alities that accompany CKD,7,8 notably CDK-mineral and
one disorders. This entity implies abnormalities in the
etabolism of calcium, phosphorus,9 vitamin D,10,11 FGF23-
lotho, and parathyroid hormone (PTH).12 To those we must
dd biological abnormalities such as dysfunctional produc-
ion of calciﬁcation inhibitors by smooth muscle cells, and
hronic inﬂammation.13 Together, these factors induce phy-
iochemical changes in the smooth muscle cells of the arterial
all, promoting their transformation into osteoblasts,14 and(http://creativecommons.org/licenses/by-nc-nd/4.0/).
hydroxyapatite deposition. Classically, the [Ca] × [P] product
has been used to determine VC risk in renal patients.15 How-
ever, some in vitro studies have demonstrated that with a
stable [Ca] × [P] product, it is the individual concentration of
each element that determines the development of VC.16
Until now, all therapeutic efforts have been directed at
controlling these metabolic abnormalities (essentially phos-
phate binders,17 vitamin D derivatives,18 and calimimetics19)
and the classical risk factors, with varying and contradictory
results. Although some of these treatments can slow progres-
sion, none have been demonstrated to reverse VC.20,21
In comparison with patients in the early stages of CKD,
patients treated with haemodialysis (HD) have higher cardio-
vascular morbidity and mortality,22 along with more  marked
abnormalities in bone metabolism and a greater degree of
VC.23,24 As well as all the previously stated mechanisms,
the biochemical changes produced during HD could play an
important role in such marked development of VC.25 In fact,
in vitro studies using rat aortas have shown that changes in
calcium and phosphorus concentrations and alkalinisation
are precipitating factors for VC.16,26 It is also known that acid-
osis protects against VC,27 therefore a high pH could have the
unfavourable opposite effect.
Aims
The aim of this study was to analyse the biochemical changes
in the parameters of mineral metabolism and acid–base bal-
ance that take place during HD.
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Fig. 1 – Temporal changes in plasma ionised calcium (mM)
during haemodialysis sessions. Patients are grouped
according to baseline ionised calcium and calcium bath
used. 100% of patients dialysed with Ca++ bath of 1.5 mM
ended the session with plasma levels >1.3 mM,
independently of the baseline calcaemia, whilst only
15% of those with a Ca++ bath of 1.25 mM reached that level450  n e f r o l o g i a. 2
Materials  and  methods
Study  design
We  prospectively studied the changes in mineral metabolism
and acid–base metabolism that occurred during haemodial-
ysis sessions. We  selected 26 stable patients with CKD who
attended HD 3 times per week at our hospital centre. Mean
patient age was 73.15 years ± 12.56 years, and 57.69% were
men. Time on HD was 1871 days (standard deviation [SD]
2516.82 days; range, 45–12 325 days). During the sessions it was
not permitted to administer medication that would interfere
with mineral metabolism or acid–base balance. All patients
gave informed consent to participate in the study.
Thirteen patients (50%) were randomly allocated to receive
dialysis with a calcium bath concentration of 1.25 mM;  the
other 13 patients received dialysis with a calcium bath con-
centration was 1.5 mM.  The dialysis ﬂuid in both groups had
the same concentrations of bicarbonate, 35 mM;  magnesium,
0.5 mM;  potassium, 1.5 mM;  and sodium, 140 mM.
All patients were conventionally dialysed over 4 h with high
ﬂow Helixona® (Fx CorDiax 80®, Fresenius Medical Care, AG,
Bad Homburg, Germany) with an ultraﬁltration coefﬁcient of
64 mL/h/mmHg or with Evodial® (HeprAN Gambro) with ultra-
ﬁltration coefﬁcient of 50 mL/h/mmHg.
Biochemical  parameters  studied
Blood samples were taken at the start of the session and sub-
sequently at 15, 30, 60, and 120 min, and at 4 h, coinciding with
the end of the session, to evaluate the changes produced in the
variables of mineral metabolism and acid–base metabolism
over the course of the HD session.
Blood pH and ionised calcium normalised for pH
(Ca++) were measured using direct potentiometry with an
ion-selective electrode (ABL80 FLEX auto-analyser). Creati-
nine, urea, phosphorus, magnesium, and bicarbonate were
measured using colourimetry (ADVIA 2400 auto-analyser.
Siemens). Intact PTH levels in the baseline sample and ﬁnal
sample were measured using immunoassay (IDS-iSYS auto-
analyser).
The calcium–phosphorus product is expressed in mg2/dL2.
The values obtained for ionised calcium in mM were converted
to mg/dL according to the molecular weight of calcium (Ca++
1 mM = 4 mg/dL).
Statistical  analysis
Results are expressed as mean and SD and 95% conﬁdence
interval. Statistical analysis was performed using Student’s t
test for independent data and a chi-square test.
ResultsThe 26 patients were classiﬁed according to their baseline cal-
cium level, into hypocalcaemic and normocalcaemic, using
the normal lower limit of Ca++ in out laboratory as a reference
(range, 1.16–1.3 mM).  The normal limits of phosphataemia(P < .001).
used were 2.5–4.5 mg/dL. The main characteristics of the sam-
ple can be seen in Table 1, with patients grouped according
to calcium bath used and baseline calcaemia. There were no
signiﬁcant differences between the groups regarding sex, age,
days on HD, ultraﬁltration, calcium bath used, or type of vas-
cular access.
Table 2 shows the baseline and ﬁnal values of the differ-
ent parameters, grouped by calcium bath used and baseline
calcium level. Table 3 shows the overall increase of each
parameter assessed, which corresponds to the difference
between the mean ﬁnal and mean baseline values. All results
are expressed as mean and SD.
In Figs. 1–5, the temporal changes in patient plasma cal-
cium (mM), phosphorus (mg/dL), Ca × P product (mg2/dL2),
bicarbonate (mM),  and pH can be seen graphically, grouped
by baseline calcium (above/below 1.16 mM)  and calcium bath
(1.25 or 1.5 mM).  Below, we describe individually the changes
in each of the parameters analysed.
Ionised  calcium
Independently of the baseline calcium level or calcium bath
used, in both groups there was an increase in calcaemia on
ﬁnishing dialysis (Table 2). Over the course of the session there
was a progressive, uniform increase in calcium (Fig. 1), which
was signiﬁcantly higher in the group of patients dialysed with
++a 1.5 mM Ca bath than in the 1.25 mM group (0.23 ± 0.08
vs 0.08 ± 0.09, P < .001) (Table 3). In the 1.5 mM group, 100%
of patients ﬁnished dialysis with plasma calcium values
>1.3 mM,  independently of the baseline calcaemia, whereas
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Table 1 – Patient characteristics, grouped by baseline calcaemia.
Calcium bath Baseline calcaemia
1.25 mM 1.5 mM <1.16 mM >1.16 mM
n 13 13 13 13
Women/Men 6/7 5/8 7/6 4/9
Ca++ bath 1.25 mM X X 7 6
Ca++ bath 1.5 mM X X 6 7
Age, years 70.23 ± 16.18 76.08 ± 6.95 72 ± 13.13 74.31 ± 12.38
Days on HD 2.410.92 ± 3.323.29 1.331.08 ± 1.233.21 1.114.23 ± 1.432.07 2.627.77 ± 3.147.22
UF, mL 18.54.58 ± 830.59 2.002.50 ± 720.95 2.075.18 ± 543.13 1.804.46 ± 915.19
AVF/CVC 6/7 7/6 4/9 9/4
Age, days on haemodialysis, and ultraﬁltration are expressed as mean ± standard deviation. There were no statistically signiﬁcant differences
between groups for any of the variables. AVF, ateriovenous ﬁstula; CVC, central venous catheter.
Table 2 – Mean baseline and ﬁnal levels of ionised calcium, phosphorus, Ca++ × P product, pH, bicarbonate, magnesium,
and PTH.
Calcium bath Baseline calcium
1.25 mM 1.5 mM <1.16 mM >1.16 mM
Calcium (mM) Baseline 1.17 ± 0.14 1.14 ± 0.09 1.07 ± 0.08 1.23 ± 0.08
Final 1.25 ± 0.09a 1.37 ± 0.04a 1.28 ± 0.10 1.34 ± 0.08
Phosphorus (mg/dL) Baseline 5.05 ± 1.74 5.04 ± 1.70 5.08 ± 1.55 5 ± 1.87
Final 2.01 ± 0.68 2.55 ± 0.82 2.31 ± 0.78 2.25 ± 0.83
Ca++ × P (mg2/dL2) Baseline 23.89 ± 9.22 22.73 ± 7.2 21.86 ± 6.90 24.76 ± 9.25
Final 10.10 ± 3.84a 13.99 ± 4.41a 11.94 ± 4.55 12.15 ± 4.65
pH Baseline 7.38 ± 0.06 7.38 ± 0.06 7.37 ± 0.06 7.39 ± 0.06
Final 7.48 ± 0.04 7.45 ± 0.06 7.46 ± 0.04 7.47 ± 0.06
Bicarbonate (mM) Baseline 24.88 ± 3.31 25.82 ± 3.57 25.59 ± 3.9 25.12 ± 2.97
Final 29.84 ± 2.01 29.98 ± 2.38 29.89 ± 2.66 29.92 ± 1.62
Magnesium (mg/dL) Baseline 2.43 ± 0.39 2.32 ± 0.42 2.38 ± 0.43 2.38 ± 0.39
Final 1.97 ± 0.17 2.04 ± 0.24 2 ± 0.23 2.01 ± 0.18
iPTH (pg/mL) Baseline 574.69 ± 379.75a 321.15 ± 244.46a 441 ± 293.44 454.85 ± 390.61
Final 496.23 ± 400.61a 229.62 ± 236.18a 296.31 ± 338.36 429.54 ± 361.48
Expressed as mean and standard deviation.
a Grouped by calcium bath used, there were statistically signiﬁcant differences in the values of ﬁnal calcium (P < .001), ﬁnal Ca++ × P (P = .02),
alcae
i
o
w
cbaseline iPTH (P = .05) and ﬁnal iPTH (P = .05). Grouped by baseline c
variables.n the 1.25 mM group this only happened in 15% (P < .001). The
verall calcium increase was signiﬁcantly higher in patients
ith a baseline calcium <1.16 mM than in those with baseline
alcium >1.16 mM (0.2 ± 0.11 vs 0.11 ± 0.11, P = .03) (Table 3).
Table 3 – Changes in ionised calcium, phosphorus, Ca++ × P pro
end of haemodialysis session, by calcium bath and baseline ca
Calcium bath 
1.25 mM 1.5 m
Ca++ (mM) 0.08 ± 0.091 0.23 ±
P (mg/dL) −3.04 ± 1.36 −2.48 ±
Ca++ × P (mg2/dL2) −13.79 ± 7.09a −8.74 ±
HCO3− (mM) 4.95 ± 2.03 4.15 ±
pH 0.10 ± 0.08 0.07 ±
Mg++ (mg/dL) −0.46 ± 0.33 −0.28 ±
PTH (pg/mL) −78.46 ± 245.44 −91.54 ±
Expressed as mean and standard deviation.
a Grouped by calcium bath, there were statistically signiﬁcant difference
(P = .04).
b Grouped by baseline calcaemia, there were statistically signiﬁcant differmia, there were no statistically signiﬁcant differences in any of the
Lastly, calcium increase and mean ﬁnal serum calcium levels
were independent of the vascular access used, and of baseline
phosphataemia: there were no statistically signiﬁcant differ-
ences between those groups.
duct, bicarbonate, pH, and magnesium, from start until
lcaemia.
Baseline calcaemia
M <1.16 mM >1.16 mM
 0.08a 0.2 ± 0.11b 0.11 ± 0.11b
 1.15 −2.78 ± 0.89 −2.75 ± 1.59
 4.17a −9.92 ± 3.37 −12.61 ± 8.13
 2.39 4.30 ± 2.05 4.81 ± 2.41
 0.07 0.09 ± 0.06 0.08 ± 0.09
 0.27 −0.38 ± 0.35 −0.37 ± 0.27
 227.45 −144.69 ± 244 −25.31 ± 211.68
s in the increase in calcium (P < .001) and the decrease in Ca++ × P
ences only in the calcium increase (P = .03).
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Fig. 2 – Temporal changes in plasma phosphorus (mg/dL)
during haemodialysis sessions. Patients are grouped
according to baseline calcium and calcium bath used.
Changes in phosphorus were  independent of the calcium
bath used and the baseline calcaemia: there were  no
signiﬁcant differences between groups.
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Fig. 3 – Temporal changes in plasma Ca++ × P product
(mg2/dL2) during haemodialysis sessions. Patients are
grouped according to baseline calcium and calcium bath
used. Those dialysed with Ca++ bath 1.25 mM had ﬁnal
Ca++ × P products signiﬁcantly lower than those of the
1.5 mM group (10.1 ± 3.84 vs 13.99 ± 4.41; P = .029). In the
1.25 mM group, the reduction in the Ca++ × P product was
signiﬁcantly greater (−13.79 ± 7.09 vs −8.74 ± 4.17; P = .04).
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Fig. 4 – Temporal changes in plasma bicarbonate (mM)
during haemodialysis sessions. Patients are grouped
according to baseline calcium and calcium bath used.
Baseline and ﬁnal values of bicarbonate were independent
of the calcium bath used and the baseline calcaemia: there
were no signiﬁcant differences between groups. 50% of
patients ended the session with baseline bicarbonate levels
>30 mM.
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Fig. 5 – Temporal changes in plasma pH during
haemodialysis sessions. Patients are grouped according to
baseline calcium and calcium bath used. The baseline and
ﬁnal values were  independent of the calcium bath used and
the baseline calcaemia: there were  no signiﬁcant
differences between groups. Overall, 23% of patients ended
the session with pH >7.5.
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hosphorus
here were no statistically signiﬁcant differences in baseline
hosphorus levels or ﬁnal phosphorus levels between groups
ccording to the baseline calcium or the calcium bath used
Table 2). During the session, there was a progressive decrease
n phosphorus, which was more  marked in the ﬁrst hours of
ialysis (Fig. 2). There were no signiﬁcant differences between
roups in the overall phosphorus decrease (Table 3). As pre-
iously mentioned, the ﬁnal serum calcium levels and the
alcium increase were independent of baseline phosphorus
evels: there were no signiﬁcant differences between groups
normal range 2.5–4.5 mg/dL).
a  ×  P  product
he baseline calcium phosphorus product was independent
f the baseline calcium and calcium bath used: there were
o signiﬁcant differences between groups (Table 2). Over the
ession, there was a fall in the Ca++ × P, which was more
arked in the ﬁrst hour (Fig. 3). Patients dialysed with a
.25 mM Ca++ bath had signiﬁcantly lower ﬁnal Ca++ × P prod-
cts than those dialysed with a 1.5 mM Ca++ bath (10.1 ± 3.84
s 13.99 ± 4.41, P = .02). Furthermore, in the 1.25 mM group,
he overall decrease in the Ca++ × P product was signiﬁcantly
reater than in the 1.5 mM group (13.79 ± 7.09 vs 8.74 ± 4.17,
 = .04) (Table 3).
icarbonate  and  pH
he baseline and ﬁnal values of bicarbonate and pH were
ndependent of the baseline calcium and calcium bath used;
here were no signiﬁcant differences between groups (Table 2).
ver the session, bicarbonate increased progressively (Fig. 4).
he pH decreased initially in the ﬁrst 30 min, with subse-
uent alkalinisation (Fig. 5). Overall, 50% of patients ended
he session with bicarbonate levels >30 mM and 23% with pH
7.5. The overall increase in bicarbonate and the alkalinisation
ere similar between groups, independently of the baseline
alcium or the calcium bath used (Table 3).
agnesium
he baseline and ﬁnal values of magnesium were independent
f the baseline calcium and calcium bath used; there were
o signiﬁcant differences between groups (Table 2). Over the
ession, there was a homogenous decrease in all groups, with
o signiﬁcant differences between groups (Table 3).
ntact  parathyroid  hormone
he baseline and ﬁnal levels of intact parathyroid hormone
iPTH) were lower in patients dialysed with a 1.5 mM calcium
ath than with a 1.25 mM bath (baseline iPHT 574 ± 379.75
s 321.15 ± 244.46; P = .05) (ﬁnal iPHT: 496.23 ± 400.61 vs
23.62 ± 236.18; P = .05) (Table 2). However, there were no dif-
erences in the changes in PTH in relation to the calcium bath
sed or the baseline calcaemia (Tables 2 and 3).(5):448–456 453
Discussion
In this study we analysed the changes produced in calcium,
phosphorus, magnesium, pH, and bicarbonate, during HD ses-
sions. The induction of alkalinisation, along with the increase
in serum calcium in the presence of hyperphosphataemia in
the initial phases of HD constitutes a perfect environment for
the development of VC.
The physiochemical mechanisms responsible for VC have
been studied in vitro. Lomashvili16 demonstrated that the cal-
ciﬁcation of rat aortas in vitro required increased calcium and
phosphorus, but was not related to the calcium–phosphorus
product. Also, De Solís et al. observed that calciﬁcation was
potentiated by alkalinisation in the presence of uraemic serum
and even more  so with the alkalinisation of the extracellular
medium (pH of 7.42–7.53).26 Furthermore, in in vivo stud-
ies, aortic calciﬁcation was proven to increase signiﬁcantly
in alkalinised animals. This is precisely what occurs during
HD and what we have observed in our study. Haemodialysis
sessions produce these physiochemical changes, which could
be responsible, along with other factors, for the development
of VC. It is the “perfect biochemical storm”, with high cal-
cium levels and alkalinisation despite a progressive reduction
in the calcium–phosphorus product. In many  patients, phos-
phorus normalisation is not achieved until after 2 h of HD,
adding another factor as there is hyperphosphataemia in the
ﬁrst hours. What occurs post-dialysis can be considered even
more  critical, as at 2 h there is a phosphorus rebound of up to
40%. To that could be added that the magnesium concentra-
tions used in the dialysis ﬂuid (0.5 mM)  produce a reduction in
serum magnesium values during HD (Tables 2 and 3), which
could augment even more  this “perfect storm” of calciﬁcation
during HD sessions. Several studies, both in vitro and in ani-
mals, have shown a protective effect of magnesium against
VC through multiple mechanisms, and clinical studies also
demonstrate evidence of this protective effect of magnesium
against VC.28,29
In our study we  used dialysis ﬂuid with a concentration
of 35 mM of bicarbonate, with plasma bicarbonate increasing
from 25.35 ± 3.4 mM to 29.91 ± 2.16 mM and pH from 7.38 ± 0.06
baseline value to 7.47 ± 0.05 ﬁnal value, with an increase to
above 7.50 in 23% of patients (independently of the calcium
bath used). These values are similar to, or even higher than,
the degree of alkalinisation that led to increased calciﬁca-
tion in rat aortas in vitro.16,26 One of the most debatable
points of this study is: if the calcium–phosphorus product
is reduced during dialysis, why does the idea remain that
dialysis induces VC. In the studies by Lomashvili, the con-
centrations of Ca++ and P were changed inversely to maintain
a constant [Ca++] × [P] product, and it was observed that VC
increased directly as calcium increased, despite a decrease
in phosphorus. That is, calciﬁcation is not a function of the
calcium–phosphorus product, but depends more  on the indi-
vidual concentrations of calcium and phosphorus.
If the hypothesis of VC during HD is reasonable, we  should
progress to how to control the physiochemical factors respon-
sible. Or rather, how to avoid the precipitating factors being
present at the same time. The ﬁrst change would relate to
the calcium concentration of the dialysis bath. The changes in
 0 1 5
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serum calcium that occur during dialysis depend on the ini-
tial serum calcium concentration, the ultraﬁltration volume,
and the calcium concentration of the dialysis ﬂuid. Calcium
kinetics during HD sessions have already been studied by var-
ious authors, using different calcium bath concentrations and
different HD tecnhiques30,31: serum calcium increased to 1.32
and 1.45 mM during HD sessions with dialysis ﬂuid calcium
concentrations of 1.25 and 1.5 mM,  respectively. Conversely,
in patients with baseline calcaemia in the normal range, the
calcium balance is neutral or negative with dialysis ﬂuid con-
centrations of 1.25 mM.32 However, as in our study, in patients
with a low baseline calcium, ionised calcium can increase
during dialysis with a 1.25 mM concentration. In reality, the
KDIGO guidelines suggest a dialysis ﬂuid calcium concen-
tration of between 1.25 and 1.50 mM,33 based on the theory
that a concentration of 1.25 mM means a neutral calcium bal-
ance. However, Gotch et al. demonstrated very different results
with 2 kinetic models. By analysing calcium transport across
the dialyser during dialysis, they observed that each session
induced more  than 500 mg  of calcium transport. In the kinetic
analysis of intestinal absorption of calcium in 320 patients on
HD, the study by Gotch concluded that calcium absorption was
strongly dependent on the dose of vitamin D analogues and
much less so on ingested calcium. The most important con-
clusion to relate to our study about possible VC during HD
was that 70% of patients who  received calcium binders and
between 20% and 50% of those who take non-calcium binders
required a dialysis ﬂuid calcium concentration lower than
1.25 mM to prevent long-term calcium build-up.34,35 However,
it must be considered that the concept of calcium gain might
not be correct, because plasma calcium is the result of sev-
eral factors involved in the homeostasis of calcium. Changes
in pH modify ionised Ca++, and alkalosis reduces free Ca++
by increasing the binding of Ca++ to albumin. Furthermore,
it must be taken into account that PTH releases calcium from
bone. In our study we  analysed ionised calcium, and therefore
the increase did not depend on calcium bound to albumin.
Also, since PTH decreased during HD, it would not be respon-
sible for an increase in release of bone calcium, so, in line with
the observations of Gotch,34,35 there would be calcium trans-
port during dialysis that could favour the calciﬁcation process,
although the reduction in phosphorus could have a certain
protective effect. All of this means that the calcium concentra-
tion in dialysis ﬂuid should be individualised36 and, if we want
to avoid calcium gain during the dialysis session, we should
also consider measures to increase the intestinal absorption of
calcium (oral Ca++ or vitamin D) to maintain a neutral balance.
During HD there is a decrease in plasma phosphorus
as it diffuses across the dialyser. This plasma decrease, in
conventional HD, leads to a nadir in approximately the ﬁrst
hour; later the phosphorus level is more  stable, as seen in our
study.37,38 This seems to be due to the kinetics of phosphate
in response to the extracellular decrease, depending on the
predialysis concentration.39 Therefore, during the ﬁrst hour
and a half, we  could individually programme dialysis, so as
to avoid calcium gain while serum phosphorus has not yet
reached its nadir. If we add to that the absence of alkalinisa-
tion with dialysis bath bicarbonate concentrations similar to,
or slightly higher than, predialysis concentrations, we  would
avoid the concurrent combination of “alkalinisation + calcium;3 5(5):448–456
gain + hyperphosphataemia”, which, combined with a
decrease in magnesium is the “perfect storm” for VC.
The hypothesis that the practice of HD sessions can induce
VC is also supported by the fact that patients who  end up on
dialysis have from 2 to 5 times more  coronary artery calci-
ﬁcation than matched nonrenal patients. Also, as coronary
calciﬁcation is closely correlated with the number of years on
HD, calciﬁcation could well be due to long duration of CKD or
long treatments with calciﬁcation inducers, such as calcium-
based phosphate binders or vitamin D compounds.40,41
This study has some weaknesses. The most important
weakness is that it was assumed that the biochemical changes
that occurred in vitro and in vivo were applicable to patients
during HD sessions. Of course, there are biological factors
that interfere in the prevention of VC that we have not
analysed.42–47 Studies would be required, directed at calciﬁ-
cation during the process of HD, in addition to the existing
studies on the progression of CKD. Another of the weaknesses
of our study is the absence of gasometry. There was a decrease
in pH at 15 min  from starting the session that theoretically
could have a protective effect against calciﬁcation.27 It is a
transient effect, which, coinciding with the increase in bicar-
bonate, logically is related to pCO2. In studies on respiratory
function during HD with bicarbonate, similar changes were
found that were explained by a pCO2 increase greater than
the bicarbonate increase.48 However, as in our study, those
authors also observed a progressive alkalinisation during HD
sessions.
In conclusion, in all the studies on VC in patients with CKD,
including international guidelines,33 classical and nonclassi-
cal factors were analysed, with special emphasis on the active
cellular process that occurs, with osteogenic transformation
and formation of hydroxyapatite in connection with abnor-
mal  calciﬁcation-inhibitory factors. Hyperphosphataemia and
especially the role of calcium-based phosphate binders in the
development of VC form a multitude of articles that defend
the use of noncalcium-based binders. However, there is lit-
tle more  in-depth study of the biochemical phenomena that
patients experience 156 times per year during HD sessions and
that clearly induce calciﬁcation: calcium gain in the presence
of hyperphosphataemia at the same time as progressive alka-
linisation. Therefore, studies are needed that individualise
HD according to the characteristics of each patient, especially
their baseline calcium and phosphorus. A delay in calcium
gain and alkalinisation until serum phosphorus has gone
down to normal values during HD sessions could be the ﬁrst
step in modifying this “perfect storm”.
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